Everolimus Safety in RCC Maintained With Expanded Access Medscape February 28, 2012 (Paris, France) — Under an expanded-access program, everolimus (Afinitor, Novartis) has a safety profile and tumor response consistent with those seen in RECORD-1 (Cancer. 2010;116:4256-4265), the registration study of patients with ... |
